Trial Outcomes & Findings for Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma (NCT NCT00904722)

NCT ID: NCT00904722

Last Updated: 2016-06-03

Results Overview

Overall response (OR) rate defined as complete response (CR) + partial response (PR). CR: Complete disappearance of all detectable clinical evidence of disease and symptoms if present before therapy. If a PET scan was positive before therapy, a post-treatment residual mass of any size was deemed a complete response provided that it was PET negative. If response was determined by CT scan criteria, lymph nodes that regressed to less than 1·5 cm were deemed to be complete response. The spleen and/or liver, if considered enlarged before therapy should not be palpable on physical examination and be considered normal size by imaging studies, and nodules related to lymphoma should disappear. PR: At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by ≥ 50% in their SPD. No new sites of disease should be observed.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

32 participants

Primary outcome timeframe

Response measured after completion of the second and fourth infusions of CT-011, and every 12 weeks thereafter for 2 years or until relapse.

Results posted on

2016-06-03

Participant Flow

Recruitment Period: January 08, 2010 to January 05, 2012. All recruitment was done at The University of Texas (UT) MD Anderson Cancer Center.

Thirty-two patients were enrolled, out of which two patients were ineligible and not treated.

Participant milestones

Participant milestones
Measure
Pidilizumab (CT-011)
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Overall Study
STARTED
30
Overall Study
COMPLETED
29
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Pidilizumab (CT-011)
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Overall Study
Physician Decision
1

Baseline Characteristics

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pidilizumab (CT-011)
n=30 Participants
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Age, Continuous
61 years
n=5 Participants
Sex: Female, Male
Female
13 Participants
n=5 Participants
Sex: Female, Male
Male
17 Participants
n=5 Participants
Region of Enrollment
United States
30 participants
n=5 Participants

PRIMARY outcome

Timeframe: Response measured after completion of the second and fourth infusions of CT-011, and every 12 weeks thereafter for 2 years or until relapse.

Population: One patient was withdrawn after one infusion of CT-011 as per the treating physician's decision.

Overall response (OR) rate defined as complete response (CR) + partial response (PR). CR: Complete disappearance of all detectable clinical evidence of disease and symptoms if present before therapy. If a PET scan was positive before therapy, a post-treatment residual mass of any size was deemed a complete response provided that it was PET negative. If response was determined by CT scan criteria, lymph nodes that regressed to less than 1·5 cm were deemed to be complete response. The spleen and/or liver, if considered enlarged before therapy should not be palpable on physical examination and be considered normal size by imaging studies, and nodules related to lymphoma should disappear. PR: At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by ≥ 50% in their SPD. No new sites of disease should be observed.

Outcome measures

Outcome measures
Measure
Pidilizumab (CT-011)
n=29 Participants
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Overall Response Rate
Complete Response
15 participants
Overall Response Rate
Partial Response
4 participants

SECONDARY outcome

Timeframe: Measured after completion of the second and fourth infusions of CT-011, and every 12 weeks thereafter for 2 years or until relapse.

Population: One patient was withdrawn after one infusion of CT-011 as per the treating physician's decision.

Progression-Free Survival (PFS) was measured from enrollment to disease progression or recurrence or death from any cause.

Outcome measures

Outcome measures
Measure
Pidilizumab (CT-011)
n=29 Participants
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Progression-Free Survival
18.8 months
Interval 14.7 to
Distributional assumptions were not available making it not possible to obtain an exact 95% confidence interval for the median.

Adverse Events

Pidilizumab (CT-011)

Serious events: 0 serious events
Other events: 30 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Pidilizumab (CT-011)
n=30 participants at risk
Combination of the immunotherapy drugs, CT-011 and Rituximab. CT-011: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days). Rituximab: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Blood and lymphatic system disorders
Anaemia
46.7%
14/30 • Number of events 14 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
General disorders
Fatigue
50.0%
15/30 • Number of events 15 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Blood and lymphatic system disorders
Leucopenia
36.7%
11/30 • Number of events 11 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Blood and lymphatic system disorders
Thrombocytopenia
33.3%
10/30 • Number of events 10 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnea
20.0%
6/30 • Number of events 6 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Blood and lymphatic system disorders
Neutropenia
20.0%
6/30 • Number of events 6 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Gastrointestinal disorders
Nausea
16.7%
5/30 • Number of events 5 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
General disorders
Sweating
13.3%
4/30 • Number of events 4 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Nervous system disorders
Neuropathy
13.3%
4/30 • Number of events 4 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Respiratory, thoracic and mediastinal disorders
Cough
13.3%
4/30 • Number of events 4 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
General disorders
Pain
16.7%
5/30 • Number of events 5 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Blood and lymphatic system disorders
Oedema
13.3%
4/30 • Number of events 4 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Skin and subcutaneous tissue disorders
Pruritus
10.0%
3/30 • Number of events 3 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Gastrointestinal disorders
Diarrhea
10.0%
3/30 • Number of events 3 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Gastrointestinal disorders
Anorexia
10.0%
3/30 • Number of events 3 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Cardiac disorders
Hypotension
10.0%
3/30 • Number of events 3 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.
Respiratory, thoracic and mediastinal disorders
Respiratory Infection
20.0%
6/30 • Number of events 6 • Adverse events were captured from Day 1 to 30 days from the last treatment by study drug.

Additional Information

Sattva S. Neelapu, MD/Associate Professor, Lymphoma/Myeloma

The University of Texas (UT) MD Anderson Cancer Center

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place